양수천자침 시장 - 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 처치별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Amniocentesis Needle Market Growth & Trends:

The global amniocentesis needle market size is anticipated to reach USD 297.35 million by 2030, expanding at a CAGR of 6.85%, based on a new report by Grand View Research, Inc. This growth can be attributed to several factors like advancements in healthcare technology, a rising prevalence of genetic disorders prompting increased demand for prenatal diagnosis, and the continuous development of minimally invasive techniques. Amniocentesis needles are in high demand as they are essential for identifying potential risks. However, there is a pressing concern within the fields of obstetrics and gynecology regarding early pregnancy loss following amniocentesis.

The rise in genetic disorders worldwide is significantly boosting the demand for precise tools such as amniocentesis needles in prenatal diagnostics. This rising prevalence of genetic conditions highlights the pressing need for accurate and early detection methods for potential issues in unborn babies. The importance of advanced tools like amniocentesis needles is underscored by the growing demand for better prenatal care due to the serious health implications of genetic disorders. For instance, a 2022 report from MJH Life Sciences highlighted the escalating global burden of genetic diseases, revealing that around 300,000 babies are born with sickle cell disease annually, affecting nearly 5% of the world's population.

The trend of women delaying childbirth to older ages has gained prevalent traction. Advanced maternal age is inherently linked to a promoted risk of chromosomal abnormalities in the fetus, rendering amniocentesis comes in as a crucial diagnostic tool. The occurrence of early abortion following amniocentesis is a significant concern within the fields of obstetrics and gynecology. It's crucial to uncover the factors that contribute to this phenomenon. Studies have reported varying incidence rates, with some suggesting rates as high as around 10%. Consequently, this age-related factor significantly propels the demand for amniocentesis needles.

Furthermore, the increasing prevalence of chronic diseases such as diabetes and hypertension among expectant mothers has increased the demand for more comprehensive prenatal screening. According to a 2021 research paper published by The Global Library of Women's Medicine, it is estimated that approximately 16.9% of pregnancies worldwide are affected by hyperglycemia during pregnancy, as per WHO criteria. The incidence of such conditions is on the rise, attributed to factors like the increasing obesity rate, advanced maternal age, and changes in screening and diagnostic criteria. Moreover, healthcare professionals increasingly acknowledge the importance of early detection of genetic disorders. Thus, amniocentesis is frequently recommended for women dealing with these health challenges, providing a crucial means to assess fetal health.

Amniocentesis Needle Market Report Highlights:

• In 2023, the 100-150 mm segment accounted for the largest market share. This can be attributed due to its optimal length, which caters to diverse clinical requirements in prenatal procedures
• The amniocentesis procedures segment dominated the procedure segment in 2023 owing to the rising demand for accurate and reliable prenatal diagnosis and increasing prevalence of genetic abnormalities
• Hospitals segment dominated the end use segment in 2023 as they offer comprehensive prenatal services, including amniocentesis, making them key users of these needles
• The North American region held the largest share of the market in 2023 due to advanced healthcare infrastructure, increased awareness about prenatal testing, higher adoption rates of advanced medical technologies, and a rising prevalence of genetic disorders
• Market players adopt several strategic initiatives to increase the product reach and improve availability in diverse geographic areas

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Procedure
  • 1.1.3. End-use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Procedure outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Amniocentesis Needle Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of gestational diabetes
    • 3.2.1.2. Increasing prevalence of genetic disorders and chromosomal abnormalities
    • 3.2.1.3. Rise in prenatal testing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risk and invasiveness
    • 3.2.2.2. Alternative non-invasive testing
• 3.3. Amniocentesis Needle Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Amniocentesis Needle Market: Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. 100 to 150 mm
  • 4.1.2. Larger Than 150 mm
  • 4.1.3. Smaller Than 100 mm
• 4.2. Type Market Share, 2018 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Amniocentesis Needle Market by Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. 100 to 150 mm
    • 4.5.1.1. 100 to 150 mm market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Smaller Than 100 mm
    • 4.5.2.1. Smaller Than 100 mm market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Larger Than 150 mm
    • 4.5.3.1. Larger Than 150 mm market estimates and forecast 2018 to 2030s (USD Million)

Chapter 5. Amniocentesis Needle Market: Procedure Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. Amniocentesis Procedures
  • 5.1.2. Amnioreduction Procedures
  • 5.1.3. Fetal Blood Transfusion
  • 5.1.4. Amnioinfusion Procedure
  • 5.1.5. Cordocentesis Procedure
• 5.2. Procedure Market Share, 2018 & 2030
• 5.3. Segment Dashboard
• 5.4. Global Amniocentesis Needle Market by Procedure Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2024 to 2030 for the following
  • 5.5.1. Amniocentesis Procedures
    • 5.5.1.1. Amniocentesis procedures market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.2. Amnioreduction Procedures
    • 5.5.2.1. Amnioreduction procedures market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.3. Fetal Blood Transfusion
    • 5.5.3.1. Fetal blood transfusion market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.4. Amnioinfusion Procedure
    • 5.5.4.1. Amnioinfusion procedure market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.5. Cordocentesis Procedure
    • 5.5.5.1. Cordocentesis Procedure market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Amniocentesis Needle Market: End-use Estimates & Trend Analysis

• 6.1. Definitions and Scope
  • 6.1.1. Hospitals
  • 6.1.2. Diagnostics Centers
  • 6.1.3. Clinics
  • 6.1.4. Others
• 6.2. End-use Market Share, 2018 & 2030
• 6.3. Segment Dashboard
• 6.4. Global Amniocentesis Needle Market by End-use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2024 to 2030 for the following
  • 6.5.1. Hospitals
    • 6.5.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.2. Diagnostic Centers
    • 6.5.2.1. Diagnostic centers market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.3. Clinics
    • 6.5.3.1. Clinics market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.4. Others
    • 6.5.4.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Amniocentesis Needle Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement scenario
    • 7.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement scenario
    • 7.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Smith's Medical
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Biopsybell Srl
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Integra LifeSciences
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Laboratoire CCD
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Cook Medical
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. RI.MOS. Srl
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. CooperSurgical
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Medline
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Rocket Medical
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Becton Dickinson and Company
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives